Why Does ANVISA Medical Device Registration in Brazil Take So Long?

Answer: ANVISA medical device registration in Brazil often takes a long time because the approval process involves multi-department review, strict regulatory requirements, limited review capacity and queuing, frequent requests for supplementary information, mandatory appointment of a Brazilian Registration Holder (BRH), and, for certain products, prior INMETRO or ANATEL certification. Actual timelines vary by product risk, file quality, and eligibility for faster pathways such as joint review or equivalence certification. Low-risk Class I/II devices typically take 8-18 months, while high-risk Class III/IV devices may take 24-48 months; some high-risk products may take 2-3 years or longer.

Published and Updated

Published: 2026-07-08 09:00; Updated: 2026-07-08 09:00

Key Summary

The main reasons for long ANVISA medical device registration timelines in Brazil include: 1) complex approval procedures involving multi-department review, such as product classification, technical files, quality systems, labeling, and post-market surveillance; 2) strict regulations requiring complete technical documentation, Portuguese labeling, and a Brazilian GMP certificate or equivalent proof; 3) limited ANVISA review personnel and queuing, with some high-risk products (Class III/IV) potentially taking 2-3 years; 4) frequent requests for supplementary information, often caused by non-compliant documents; 5) the need to appoint a Brazilian Registration Holder (BRH) and complete localization agency arrangements; 6) some products must first obtain INMETRO certification or ANATEL certification, such as those with wireless functions. Actual timelines depend on product risk, file quality, and whether the product enters a faster pathway such as joint review or equivalence certification. Low-risk Class I/II devices usually take 8-18 months, while high-risk Class III/IV devices may take 24-48 months.

Applicable Scenarios and Core Questions

Companies searching for why ANVISA medical device registration in Brazil takes so long usually want practical answers, not just conceptual explanations. They need to determine whether their existing documentation can support a Brazilian submission, whether they need a local agent or authorized representative, why the timeline is extended, and which issues could affect their market launch plan. Behind this question are often product classification, registration pathway, evidence chain, labeling localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering one country's process alone is not enough. A more valuable approach is to first build reusable versions of core technical files, quality system evidence, performance verification, clinical evidence, and labeling/instructions for use, and then adapt them to each country's regulatory requirements.

Registration Assessment Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method of body contact, duration of use, sterility, whether it is active, and whether it contains software or has IVD attributes. They should then determine the risk class and submission pathway. If the pathway is incorrect, subsequent translation, notarization, authorization, testing, and supplementary information will all move in the wrong direction.

For Brazil projects, companies must also confirm the applicant entity and local responsibility boundaries: who holds the certificate, who handles regulatory communication, who manages importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control can easily be affected later.

Core Documents and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical files, performance verification reports, risk management files, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance information.

The key to document quality is not quantity but consistency. Claims in the instructions for use, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and information in the registration application form must support one another. Regulators focus on whether the product is safe, effective, and traceable for its intended use, not on whether the company has uploaded many documents.

Common Mistakes

• Submitting directly translated NMPA documents without rearranging the evidence according to Brazil's pathway.
• Including too many models and specifications while test reports, clinical evidence, or labeling coverage is insufficient.
• Selecting a local agent only based on sales cooperation without clarifying regulatory responsibilities, certificate control rights, and post-market maintenance duties.
• Inconsistencies among labels, instructions for use, promotional materials, and registration claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, causing repeated preparation for each country and increasing both cost and timeline.

Company Preparation Checklist

• Organize the target product list, model and specification matrix, and intended use statements.
• Review whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management files, clinical evaluations, and English instructions for use.
• Confirm the local agent's or authorized representative's responsibilities, fees, certificate control rights, and exit mechanism.
• Establish a target-country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view Brazilian registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear core technical file and evidence matrix and then converting it according to each country's requirements is usually faster, more stable, and more conducive to later changes and renewals than preparing documents country by country on an ad hoc basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the document and evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Frequently Asked Follow-up Questions

Can domestic Chinese documents be used directly for Brazilian registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, certificate maintenance, changes, renewals, and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Continue Reading

• Previous article: What Core Documents Are Required for UAE MOHAP Medical Device Registration?
• Next article: What Is the Difference Between a Vietnamese Medical Device Import License and Registration Certificate?

Recommended Reading

• What Should Companies Prepare Before Australian TGA Medical Device Registration?
• Can CE Documents Be Reused for Singapore HSA Medical Device Registration?
• What Core Documents Are Required for UAE MOHAP Medical Device Registration?
• What Is the Difference Between a Vietnamese Medical Device Import License and Registration Certificate?
• How Should Companies Choose a Local Agent for Indonesian Medical Device Registration?
• Will Incomplete Documents Be Returned for Thai TFDA Medical Device Registration?

Return to FAQ Center

News and Information | Contact AIMEILI

Content Review and Applicable Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as auxiliary references. Applicable boundary: this article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.

Source note: Compiled from AIMEILI registration practice resources, the medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation.